Role of chemokines polymorphisms in diseases

Immunology Letters

Volumn 145, Issue 1-2, 2012, Pages 15-22

  Guergnon, J ^a   Combadiere C ^a,b  

^a INSERM   (France)

^b ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

Author keywords

Auto immunity; Cancer; Cardiovascular diseases; Chemokines; Infectious diseases; Inflammation; Polymorphisms

Indexed keywords

CHEMOKINE; CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; CHEMOKINE RECEPTOR CCR7; INTERFERON; INTERLEUKIN 8; MONOCYTE CHEMOTACTIC PROTEIN 1; RANTES;

ACUTE GRANULOCYTIC LEUKEMIA; ALZHEIMER DISEASE; ARTICLE; ATOPIC DERMATITIS; BRAIN INFARCTION; CANCER RISK; CANCER SURVIVAL; CCL2 GENE; CCL5 GENE; CCR5 GENE; CCR7 GENE; COLORECTAL CANCER; CXCL8 GENE; DISEASE ASSOCIATION; FLAVIVIRUS INFECTION; GENE FUNCTION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE PHENOTYPE CORRELATION; GLIOBLASTOMA; GRAFT REJECTION; HEART INFARCTION; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTENSION; INFECTION RESISTANCE; INFECTION RISK; INFECTION SENSITIVITY; LUNG CANCER; MUCOCUTANEOUS LYMPH NODE SYNDROME; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN FUNCTION; RECEPTOR GENE; RETINA MACULA AGE RELATED DEGENERATION; RHEUMATOID ARTHRITIS; SINGLE NUCLEOTIDE POLYMORPHISM; SJOEGREN SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS; VIRUS TRANSMISSION; WEST NILE FLAVIVIRUS;

EID: 84862193041     PISSN: 01652478     EISSN: 18790542     Source Type: Journal    
DOI: 10.1016/j.imlet.2012.04.010     Document Type: Review

References (100)

1. Deng H., Liu R., Ellmeier W., Choe S., Unutmaz D., Burkhart M., et al. Identification of a major co-receptor for primary isolates of HIV-1. Nature 1996, 381:661-666.
2. + cells is mediated by the chemokine receptor CC-CKR-5. Nature 1996, 381:667-673.
3. Alkhatib G., Combadiere C., Broder C.C., Feng Y., Kennedy P.E., Murphy P.M., et al. CKR5: a RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1. Science 1996, 272:1955-1958.
4. Dean M., Carrington M., Winkler C., Huttley G.A., Smith M.W., Allikmets R., et al. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study. Science 1996, 273:1856-1862.
5. Huang Y., Paxton W.A., Wolinsky S.M., Neumann A.U., Zhang L., He T., et al. The role of a mutant CCR5 allele in HIV-1 transmission and disease progression. Nat Med 1996, 2:1240-1243.
6. Lucotte G., Dieterlen F. More about the Viking hypothesis of origin of the delta32 mutation in the CCR5 gene conferring resistance to HIV-1 infection. Infect Genet Evol 2003, 3:293-295.
7. Galvani A.P., Slatkin M. Evaluating plague and smallpox as historical selective pressures for the CCR5-Delta 32 HIV-resistance allele. Proc Natl Acad Sci USA 2003, 100:15276-15279.
8. Martin M.P., Dean M., Smith M.W., Winkler C., Gerrard B., Michael N.L., et al. Genetic acceleration of AIDS progression by a promoter variant of CCR5. Science 1998, 282:1907-1911.
9. Kostrikis L.G., Huang Y., Moore J.P., Wolinsky S.M., Zhang L., Guo Y., et al. A chemokine receptor CCR2 allele delays HIV-1 disease progression and is associated with a CCR5 promoter mutation. Nat Med 1998, 4:350-353.
10. McDermott D.H., Zimmerman P.A., Guignard F., Kleeberger C.A., Leitman S.F., Murphy P.M. CCR5 promoter polymorphism and HIV-1 disease progression. Multicenter AIDS Cohort Study (MACS). Lancet 1998, 352:866-870.
11. Smith M.W., Dean M., Carrington M., Winkler C., Huttley G.A., Lomb D.A., et al. Contrasting genetic influence of CCR2 and CCR5 variants on HIV-1 infection and disease progression. Hemophilia Growth and Development Study (HGDS), Multicenter AIDS Cohort Study (MACS), Multicenter Hemophilia Cohort Study (MHCS), San Francisco City Cohort (SFCC), ALIVE Study. Science 1997, 277:959-965.
12. Mangano A., Kopka J., Batalla M., Bologna R., Sen L. Protective effect of CCR2-64I and not of CCR5-delta32 and SDF1-3'A in pediatric HIV-1 infection. J Acquir Immune Defic Syndr 2000, 23:52-57.
13. Mulherin S.A., O'Brien T.R., Ioannidis J.P., Goedert J.J., Buchbinder S.P., Coutinho R.A., et al. Effects of CCR5-Delta32 and CCR2-64I alleles on HIV-1 disease progression: the protection varies with duration of infection. AIDS 2003, 17:377-387.
14. Gonzalez E., Dhanda R., Bamshad M., Mummidi S., Geevarghese R., Catano G., et al. Global survey of genetic variation in CCR5, RANTES, and MIP-1alpha: impact on the epidemiology of the HIV-1 pandemic. Proc Natl Acad Sci USA 2001, 98:5199-5204.
15. McDermott D.H., Beecroft M.J., Kleeberger C.A., Al-Sharif F.M., Ollier W.E., Zimmerman P.A., et al. Chemokine RANTES promoter polymorphism affects risk of both HIV infection and disease progression in the Multicenter AIDS Cohort Study. AIDS 2000, 14:2671-2678.
16. Shao W., Tang J., Song W., Wang C., Li Y., Wilson C.M., et al. CCL3L1 and CCL4L1: variable gene copy number in adolescents with and without human immunodeficiency virus type 1 (HIV-1) infection. Genes Immun 2007, 8:224-231.
17. Field S.F., Howson J.M., Maier L.M., Walker S., Walker N.M., Smyth D.J., et al. Experimental aspects of copy number variant assays at CCL3L1. Nat Med 2009, 15:1115-1117.
18. Bhattacharya T., Stanton J., Kim E.Y., Kunstman K.J., Phair J.P., Jacobson L.P., et al. C.C.L3L1 and HIV/AIDS susceptibility. Nat Med 2009, 15:1112-1115.
19. Huik K., Sadam M., Karki T., Avi R., Krispin T., Paap P., et al. CCL3L1 copy number is a strong genetic determinant of HIV seropositivity in Caucasian intravenous drug users. J Infect Dis 2010, 201:730-739.
20. Winkler C., Modi W., Smith M.W., Nelson G.W., Wu X., Carrington M., et al. Genetic restriction of AIDS pathogenesis by an SDF-1 chemokine gene variant. ALIVE Study, Hemophilia Growth and Development Study (HGDS), Multicenter AIDS Cohort Study (MACS), Multicenter Hemophilia Cohort Study (MHCS), San Francisco City Cohort (SFCC). Science 1998, 279:389-393.
21. Shirozu M., Nakano T., Inazawa J., Tashiro K., Tada H., Shinohara T., et al. Structure and chromosomal localization of the human stromal cell-derived factor 1 (SDF1) gene. Genomics 1995, 28:495-500.
22. + T cell decrease in advanced human immunodeficiency virus type 1 infection. J Infect Dis 2000, 182:311-315.
23. Sei S., Boler A.M., Nguyen G.T., Stewart S.K., Yang Q.E., Edgerly M., et al. Protective effect of CCR5 delta 32 heterozygosity is restricted by SDF-1 genotype in children with HIV-1 infection. AIDS 2001, 15:1343-1352.
24. Soriano A., Martinez C., Garcia F., Plana M., Palou E., Lejeune M., et al. Plasma stromal cell-derived factor (SDF)-1 levels, SDF1-3'A genotype, and expression of CXCR4 on T lymphocytes: their impact on resistance to human immunodeficiency virus type 1 infection and its progression. J Infect Dis 2002, 186:922-931.
25. Hellier S., Frodsham A.J., Hennig B.J., Klenerman P., Knapp S., Ramaley P., et al. Association of genetic variants of the chemokine receptor CCR5 and its ligands, RANTES and MCP-2, with outcome of HCV infection. Hepatology 2003, 38:1468-1476.
26. Goulding C., McManus R., Murphy A., MacDonald G., Barrett S., Crowe J., et al. The CCR5-delta32 mutation: impact on disease outcome in individuals with hepatitis C infection from a single source. Gut 2005, 54:1157-1161.
27. Ruiz-Ferrer M., Barroso N., Antinolo G., Aguilar-Reina J. Analysis of CCR5-Delta 32 and CCR2-V64I polymorphisms in a cohort of Spanish HCV patients using real-time polymerase chain reaction and fluorescence resonance energy transfer technologies. J Viral Hepat 2004, 11:319-323.
28. Muhlbauer M., Bosserhoff A.K., Hartmann A., Thasler W.E., Weiss T.S., Herfarth H., et al. A novel MCP-1 gene polymorphism is associated with hepatic MCP-1 expression and severity of HCV-related liver disease. Gastroenterology 2003, 125:1085-1093.
29. Park B.L., Kim Y.J., Cheong H.S., Kim L.H., Choi Y.H., Lee H.S., et al. Association of common promoter polymorphisms of MCP1 with hepatitis B virus clearance. Exp Mol Med 2006, 38:694-702.
30. Glass W.G., McDermott D.H., Lim J.K., Lekhong S., Yu S.F., Frank W.A., et al. CCR5 deficiency increases risk of symptomatic West Nile virus infection. J Exp Med 2006, 203:35-40.
31. Lim J.K., Louie C.Y., Glaser C., Jean C., Johnson B., Johnson H., et al. Genetic deficiency of chemokine receptor CCR5 is a strong risk factor for symptomatic West Nile virus infection: a meta-analysis of 4 cohorts in the US epidemic. J Infect Dis 2008, 197:262-265.
32. Glass W.G., Lim J.K., Cholera R., Pletnev A.G., Gao J.L., Murphy P.M. Chemokine receptor CCR5 promotes leukocyte trafficking to the brain and survival in West Nile virus infection. J Exp Med 2005, 202:1087-1098.
33. Miller L.H., Mason S.J., Dvorak J.A., McGinniss M.H., Rothman I.K. Erythrocyte receptors for (Plasmodium knowlesi) malaria: Duffy blood group determinants. Science 1975, 189:561-563.
34. Miller L.H., Mason S.J., Clyde D.F., McGinniss M.H. The resistance factor to Plasmodium vivax in blacks. The Duffy-blood-group genotype, FyFy. N Engl J Med 1976, 295:302-304.
35. Tournamille C., Colin Y., Cartron J.P., Le Van Kim C. Disruption of a GATA motif in the Duffy gene promoter abolishes erythroid gene expression in Duffy-negative individuals. Nat Genet 1995, 10:224-228.
36. Langhi D.M., Bordin J.O. Duffy blood group and malaria. Hematology 2006, 11:389-398.
37. Darbonne W.C., Rice G.C., Mohler M.A., Apple T., Hebert C.A., Valente A.J., et al. Red blood cells are a sink for interleukin 8, a leukocyte chemotaxin. J Clin Invest 1991, 88:1362-1369.
38. Neote K., Darbonne W., Ogez J., Horuk R., Schall T.J. Identification of a promiscuous inflammatory peptide receptor on the surface of red blood cells. J Biol Chem 1993, 268:12247-12249.
39. Horuk R., Chitnis C.E., Darbonne W.C., Colby T.J., Rybicki A., Hadley T.J., et al. A receptor for the malarial parasite Plasmodium vivax: the erythrocyte chemokine receptor. Science 1993, 261:1182-1184.
40. Chertow G.M., Milford E.L., Mackenzie H.S., Brenner B.M. Antigen-independent determinants of cadaveric kidney transplant failure. JAMA 1996, 276:1732-1736.
41. Abdi R., Tran T.B., Sahagun-Ruiz A., Murphy P.M., Brenner B.M., Milford E.L., et al. Chemokine receptor polymorphism and risk of acute rejection in human renal transplantation. J Am Soc Nephrol 2002, 13:754-758.
42. Yigit B., Bozkurt N., Berber I., Titiz I., Isbir T. Analysis of CC chemokine receptor 5 and 2 polymorphisms and renal transplant survival. Cell Biochem Funct 2007, 25:423-426.
43. Kruger B., Schroppel B., Ashkan R., Marder B., Zulke C., Murphy B., et al. A monocyte chemoattractant protein-1 (MCP-1) polymorphism and outcome after renal transplantation. J Am Soc Nephrol 2002, 13:2585-2589.
44. Franco-Lopez E., Gonzalez-Escribano M.F., Aguilera I., Pascasio J.M., Pareja F., Bernardos A., et al. Lack of association of recipient MCP-1 gene promoter polymorphism with acute graft rejection after orthotopic liver transplantation. Transplant Proc 2005, 37:1496-1498.
45. Colobran R., Casamitjana N., Roman A., Faner R., Pedrosa E., Arostegui J.I., et al. Copy number variation in the CCL4L gene is associated with susceptibility to acute rejection in lung transplantation. Genes Immun 2009, 10:254-259.
46. Bogunia-Kubik K., Jaskula E., Lange A. The presence of functional CCR5 and EBV reactivation after allogeneic haematopoietic stem cell transplantation. Bone Marrow Transplant 2007, 40:145-150.
47. Loeffler J., Steffens M., Arlt E.M., Toliat M.R., Mezger M., Suk A., et al. Polymorphisms in the genes encoding chemokine receptor 5, interleukin-10, and monocyte chemoattractant protein 1 contribute to cytomegalovirus reactivation and disease after allogeneic stem cell transplantation. J Clin Microbiol 2006, 44:1847-1850.
48. Rovin B.H., Lu L., Zhang X. A novel interleukin-8 polymorphism is associated with severe systemic lupus erythematosus nephritis. Kidney Int 2002, 62:261-265.
49. Tucci M., Barnes E.V., Sobel E.S., Croker B.P., Segal M.S., Reeves W.H., et al. Strong association of a functional polymorphism in the monocyte chemoattractant protein 1 promoter gene with lupus nephritis. Arthritis Rheum 2004, 50:1842-1849.
50. Nakashima H., Akahoshi M., Shimizu S., Inoue Y., Miyake K., Ninomiya I., et al. Absence of association between the MCP-1 gene polymorphism and histological phenotype of lupus nephritis. Lupus 2004, 13:165-167.
51. Brown K.S., Nackos E., Morthala S., Jensen L.E., Whitehead A.S., Von Feldt J.M. Monocyte chemoattractant protein-1: plasma concentrations and A(-2518)G promoter polymorphism of its gene in systemic lupus erythematosus. J Rheumatol 2007, 34:740-746.
52. Sanchez E., Sabio J.M., Callejas J.L., de Ramon E., Garcia-Portales R., Garcia-Hernandez F.J., et al. Association study of genetic variants of pro-inflammatory chemokine and cytokine genes in systemic lupus erythematosus. BMC Med Genet 2006, 7:48.
53. Lee Y.H., Woo J.H., Choi S.J., Ji J.D., Song G.G. Functional monocyte chemoattractant protein-1 promoter -2518 polymorphism and systemic lupus erythematosus: a meta-analysis. Mol Biol Rep 2009, 37:3421-3426.
54. Malafronte P., Vieira J.M., Pereira A.C., Krieger J.E., Barros R.T., Woronik V. Association of the MCP-1 -2518 A/G polymorphism and no association of its receptor CCR2 -64V/I polymorphism with lupus nephritis. J Rheumatol 2010, 37:776-782.
55. Petrek M., Cermakova Z., Hutyrova B., Micekova D., Drabek J., Rovensky J., et al. CC chemokine receptor 5 and interleukin-1 receptor antagonist gene polymorphisms in patients with primary Sjogren's syndrome. Clin Exp Rheumatol 2002, 20:701-703.
56. Kahlmann D., Davalos-Misslitz A.C., Ohl L., Stanke F., Witte T., Forster R. Genetic variants of chemokine receptor CCR7 in patients with systemic lupus erythematosus, Sjogren's syndrome and systemic sclerosis. BMC Genet 2007, 8:33.
57. Breunis W.B., Biezeveld M.H., Geissler J., Kuipers I.M., Lam J., Ottenkamp J., et al. Polymorphisms in chemokine receptor genes and susceptibility to Kawasaki disease. Clin Exp Immunol 2007, 150:83-90.
58. Jhang W.K., Kang M.J., Jin H.S., Yu J., Kim B.J., Kim B.S., et al. The CCR5 (-2135C/T) polymorphism may be associated with the development of Kawasaki disease in Korean children. J Clin Immunol 2009, 29:22-28.
59. Chaudhuri K., Singh Ahluwalia T., Singh S., Binepal G., Khullar M. Polymorphism in the promoter of the CCL5 gene (CCL5G-403A) in a cohort of North Indian children with Kawasaki disease. A preliminary study. Clin Exp Rheumatol 2011.
60. Garred P., Madsen H.O., Petersen J., Marquart H., Hansen T.M., Freiesleben Sorensen S., et al. CC chemokine receptor 5 polymorphism in rheumatoid arthritis. J Rheumatol 1998, 25:1462-1465.
61. Zapico I., Coto E., Rodriguez A., Alvarez C., Torre J.C., Alvarez V. CCR5 (chemokine receptor-5) DNA-polymorphism influences the severity of rheumatoid arthritis. Genes Immun 2000, 1:288-289.
62. + T cells from patients with rheumatoid arthritis. Clin Exp Immunol 2003, 132:371-378.
63. Yang P.T., Kasai H., Zhao L.J., Xiao W.G., Tanabe F., Ito M. Increased CCR4 expression on circulating CD4(+) T cells in ankylosing spondylitis, rheumatoid arthritis and systemic lupus erythematosus. Clin Exp Immunol 2004, 138:342-347.
64. Kochi Y., Okada Y., Suzuki A., Ikari K., Terao C., Takahashi A., et al. A regulatory variant in CCR6 is associated with rheumatoid arthritis susceptibility. Nat Genet 2010, 42:515-519.
65. Nickel R.G., Casolaro V., Wahn U., Beyer K., Barnes K.C., Plunkett B.S., et al. Atopic dermatitis is associated with a functional mutation in the promoter of the C-C chemokine RANTES. J Immunol 2000, 164:1612-1616.
66. Szalai C., Kozma G.T., Nagy A., Bojszko A., Krikovszky D., Szabo T., et al. Polymorphism in the gene regulatory region of MCP-1 is associated with asthma susceptibility and severity. J Allergy Clin Immunol 2001, 108:375-381.
67. Holla L.I., Mrazek F., Petrek M. MCP-1 and CCR2 gene polymorphisms in Czech patients with allergic disorders. Int J Immunogenet 2009, 36:69-72.
68. Pease J.E., Williams T.J. Chemokines and their receptors in allergic disease. J Allergy Clin Immunol 2006, 118:305-318. quiz 319-320.
69. Wise E.L., Bonner K.T., Williams T.J., Pease J.E. A single nucleotide polymorphism in the CCR3 gene ablates receptor export to the plasma membrane. J Allergy Clin Immunol 2010, 126:150-157. e152.
70. Burger J.A., Kipps T.J. CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment. Blood 2006, 107:1761-1767.
71. Dommange F., Cartron G., Espanel C., Gallay N., Domenech J., Benboubker L., et al. CXCL12 polymorphism and malignant cell dissemination/tissue infiltration in acute myeloid leukemia. FASEB J 2006, 20:1913-1915.
72. Pemberton N.C., Paneesha S., Hiller L., Starczynski J., Hooper L., Pepper C., et al. The SDF-1 G>A polymorphism at position 801 plays no role in multiple myeloma but may contribute to an inferior cause-specific survival in chronic lymphocytic leukemia. Leuk Lymphoma 2006, 47:1239-1244.
73. van Dongen J.J., Seriu T., Panzer-Grumayer E.R., Biondi A., Pongers-Willemse M.J., Corral L., et al. Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood. Lancet 1998, 352:1731-1738.
74. Davies S.M., Borowitz M.J., Rosner G.L., Ritz K., Devidas M., Winick N., et al. Pharmacogenetics of minimal residual disease response in children with B-precursor acute lymphoblastic leukemia: a report from the Children's Oncology Group. Blood 2008, 111:2984-2990.
75. Campa D., Zienolddiny S., Maggini V., Skaug V., Haugen A., Canzian F. Association of a common polymorphism in the cyclooxygenase 2 gene with risk of non-small cell lung cancer. Carcinogenesis 2004, 25:229-235.
76. Reyes-Gibby C.C., Spitz M., Wu X., Merriman K., Etzel C., Bruera E., et al. Cytokine genes and pain severity in lung cancer: exploring the influence of TNF-alpha-308 G/A IL6-174G/C and IL8-251T/A. Cancer Epidemiol Biomarkers Prev 2007, 16:2745-2751.
77. Coelho A., Calcada C., Catarino R., Pinto D., Fonseca G., Medeiros R. CXCL12-3' A polymorphism and lung cancer metastases protection: new perspectives in immunotherapy. Cancer Immunol Immunother 2006, 55:639-643.
78. Iwakiri S., Mino N., Takahashi T., Sonobe M., Nagai S., Okubo K., et al. Higher expression of chemokine receptor CXCR7 is linked to early and metastatic recurrence in pathological stage I nonsmall cell lung cancer. Cancer 2009, 115:2580-2593.
79. Lee Y.L., Kuo W.H., Lin C.W., Chen W., Cheng W.E., Chen S.C., et al. Association of genetic polymorphisms of CXCL12/SDF1 gene and its receptor, CXCR4, to the susceptibility and prognosis of non-small cell lung cancer. Lung Cancer 2011.
80. Rodero M., Marie Y., Coudert M., Blondet E., Mokhtari K., Rousseau A., et al. Polymorphism in the microglial cell-mobilizing CX3CR1 gene is associated with survival in patients with glioblastoma. J Clin Oncol 2008, 26:5957-5964.
81. Dimberg J., Dienus O., Lofgren S., Hugander A., Wagsater D. Polymorphisms of Fractalkine receptor CX3CR1 and plasma levels of its ligand CX3CL1 in colorectal cancer patients. Int J Colorectal Dis 2007, 22:1195-1200.
82. Dimberg J., Dienus O., Lofgren S., Hugander A., Wagsater D. Expression and gene polymorphisms of the chemokine CXCL5 in colorectal cancer patients. Int J Oncol 2007, 31:97-102.
83. Dimberg J., Hugander A., Lofgren S., Wagsater D. Polymorphism and circulating levels of the chemokine CXCL12 in colorectal cancer patients. Int J Mol Med 2007, 19:11-15.
84. Hidalgo-Pascual M., Galan J.J., Chaves-Conde M., Ramirez-Armengol J.A., Moreno C., Calvo E., et al. Analysis of CXCL12 3'UTR G>A polymorphism in colorectal cancer. Oncol Rep 2007, 18:1583-1587.
85. Mettimano M., Specchia M.L., Ianni A., Arzani D., Ricciardi G., Savi L., et al. CCR5 and CCR2 gene polymorphisms in hypertensive patients. Br J Biomed Sci 2003, 60:19-21.
86. Zhang M., Ardlie K., Wacholder S., Welch R., Chanock S., O'Brien T.R. Genetic variations in CC chemokine receptors and hypertension. Am J Hypertens 2006, 19:67-72.
87. Tucci M., Quatraro C., Frassanito M.A., Silvestris F. Deregulated expression of monocyte chemoattractant protein-1 (MCP-1) in arterial hypertension: role in endothelial inflammation and atheromasia. J Hypertens 2006, 24:1307-1318.
88. Penz P., Bucova M., Lietava J., Blazicek P., Paulovicova E., Mrazek F., et al. MCP-1 -2518 A/G gene polymorphism is associated with blood pressure in ischemic heart disease asymptomatic subjects. Bratisl Lek Listy 2010, 111:420-425.
89. Lavergne E., Labreuche J., Daoudi M., Debre P., Cambien F., Deterre P., et al. Adverse associations between CX3CR1 polymorphisms and risk of cardiovascular or cerebrovascular disease. Arterioscler Thromb Vasc Biol 2005, 25:847-853.
90. Apostolakis S., Amanatidou V., Papadakis E.G., Spandidos D.A. Genetic diversity of CX3CR1 gene and coronary artery disease: new insights through a meta-analysis. Atherosclerosis 2009, 207:8-15.
91. Matzhold E.M., Trummer O., Grunbacher G., Zulus B., Boehm B.O., Marz W., et al. Association of polymorphisms in the chemokine receptor CX3CR1 gene with coronary artery disease. Cytokine 2009, 47:224-227.
92. Ogimoto A., Okayama H., Nagai T., Ohtsuka T., Suzuki J., Inoue K., et al. Association of monocyte chemoattractant protein 1 gene polymorphism with susceptibility to nonfamilial idiopathic dilated cardiomyopathy. J Cardiol 2009, 54:66-70.
93. Zee R.Y., Cook N.R., Cheng S., Erlich H.A., Lindpaintner K., Lee R.T., et al. Threonine for alanine substitution in the eotaxin (CCL11) gene and the risk of incident myocardial infarction. Atherosclerosis 2004, 175:91-94.
94. Fenoglio C., Galimberti D., Lovati C., Guidi I., Gatti A., Fogliarino S., et al. MCP-1 in Alzheimer's disease patients: A-2518G polymorphism and serum levels. Neurobiol Aging 2004, 25:1169-1173.
95. Pola R., Flex A., Gaetani E., Proia A.S., Papaleo P., Di Giorgio A., et al. Monocyte chemoattractant protein-1 (MCP-1) gene polymorphism and risk of Alzheimer's disease in Italians. Exp Gerontol 2004, 39:1249-1252.
96. Li K., Dai D., Yao L., Gu X., Luan K., Tian W., et al. Association between the macrophage inflammatory protein-l alpha gene polymorphism and Alzheimer's disease in the Chinese population. Neurosci Lett 2008, 433:125-128.
97. Tuo J., Smith B.C., Bojanowski C.M., Meleth A.D., Gery I., Csaky K.G., et al. The involvement of sequence variation and expression of CX3CR1 in the pathogenesis of age-related macular degeneration. FASEB J 2004, 18:1297-1299.
98. Chan C.C., Tuo J., Bojanowski C.M., Csaky K.G., Green W.R. Detection of CX3CR1 single nucleotide polymorphism and expression on archived eyes with age-related macular degeneration. Histol Histopathol 2005, 20:857-863.
99. Combadiere C., Feumi C., Raoul W., Keller N., Rodero M., Pezard A., et al. CX3CR1-dependent subretinal microglia cell accumulation is associated with cardinal features of age-related macular degeneration. J Clin Invest 2007, 117:2920-2928.
100. Yang X., Hu J., Zhang J., Guan H. Polymorphisms in CFH, HTRA1 and CX3CR1 confer risk to exudative age-related macular degeneration in Han Chinese. Br J Ophthalmol 2010, 94:1211-1214.